Literature DB >> 6825406

The problem of avascular necrosis of bone in patients treated for Hodgkin's disease.

J J Mould, N M Adam.   

Abstract

Seven patients treated for Hodgkin's disease by chemotherapy and radiotherapy developed avascular necrosis of the heads of long bones (femur in six cases, humerus in one case). The use of steroids has been correlated with the appearance of this uncommon complication but steroids may not be the only aetiological factor. The roles of radiotherapy, chemotherapeutic agents and trauma have not been clarified in previously published accounts. The importance of trauma as a cofactor is emphasised and it is suggested that patients at risk try to avoid trauma and excessive mechanical stress. The role of radiation is less clear, though shielding the heads of long bones is recommended when clinically appropriate. Early orthopaedic referral with hip-joint replacement or bone grafting reduces the short-term morbidity of this condition, though the long-term prognosis after surgery is uncertain. Although this complication of treatment is uncommon it may inflict disability and occupational disturbance on otherwise healthy patients who have the prospect of long-term survival.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6825406     DOI: 10.1016/s0009-9260(83)80314-6

Source DB:  PubMed          Journal:  Clin Radiol        ISSN: 0009-9260            Impact factor:   2.350


  3 in total

1.  Case report 669: Osteonecrosis of bone associated with intraarterial therapy using cisplatin.

Authors:  P Wuisman; R Erlemann; A Roessner; A Bosse; C Kusniez-Glaz
Journal:  Skeletal Radiol       Date:  1991       Impact factor: 2.199

Review 2.  The late effects of cancer therapy in childhood.

Authors:  P H Morris Jones
Journal:  Br J Cancer       Date:  1991-07       Impact factor: 7.640

3.  The prevalence of avascular necrosis in patients treated with chemotherapy for testicular tumours.

Authors:  A M Cook; A S Dzik-Jurasz; A R Padhani; A Norman; R A Huddart
Journal:  Br J Cancer       Date:  2001-11-30       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.